Haematopoietic stem cells (HSCs) are capable of self-renewing and multi-lineage reconstitution of the haematopoietic system of irradiated recipient mice. In the mouse embryo, HSCs originate in a step-wise manner from the haematogenic endothelium. The first HSC precursor has been detected at E9.5 in the dorsal aorta, while HSCs emerge in the aorta-gonad-mesonephros (AGM) region around E11. To date, the molecular mechanisms regulating these events are poorly characterized. Through the activating role of Angiopoietin1 (Ang1) on Tie2 receptor, the Ang-Tie signalling pathway plays a critical role in HSC maintenance in the adult bone marrow niche. Tie2 ligand Angiopoietin2 (Ang2) is described as being a Tie2 inhibitor, however its role is unknown. The aim of this thesis was to characterise the role of Ang-Tie signalling pathway in HSC formation in the mouse embryo. First, I used an ex vivo aggregate system to culture with angiopoietins cells derived from the AGM region at stages of development preceding HSC formation (E9.5-E11). Ang2- treated cells were able to reconstitute the peripheral blood of recipient mice to a higher extent compared to control, indicating a role for Ang2 in promoting HSC maturation. Then, I characterized the expression pattern of Ang-Tie molecules in the AGM region. Ang2-expressing cells were identified as perivascular and sub-aortic mesenchymal cells located in the ventral side of the aorta and in proximity of intra-aortic haematopoietic clusters. Finally, I performed an RNA-seq analysis with the aim of unravelling the molecular mechanisms involved in Ang2-mediated HSC maturation. Pre-HSC-I were cultured in presence or absence of Ang2 and their transcriptional profiles were compared, revealing a number of genes and pathways up-regulated or down-regulated in presence of Ang2, which might indicate a role for Ang2 in increasing cell proliferation, favouring cell migration, and regulation of other signalling pathways involved in HSC development. All together, these data support Ang2 as a novel regulator for HSC formation.

Embryonic haematopoiesis is a complex process under intensive research. Murine definitive Haematopoietic Stem Cells (HSCs) originates from the Aorta-Gonad-Mesonephros (AGM) region of E10.5 embryo. It is thought that definitive HSCs arise from endothelial lining of dorsal aorta. However, detail of HSC specification in the developing embryo remains elusive. One way to deciphering events occurred during HSC specification is to derive cell lines from the developing HSC niche. Previous work by Oostendorp et al. showed the AGM and fetal liver derived lines could maintain HSCs in vitro (Oostendorp, Harvey et al. 2002). In this study, I established a more robust immortalization system using normal SV40 large T antigen delivered via Neon™ electroporation system. The new immortalization system achieved direct immortalization without going through crisis. And it is compatible with small number of primary cells dissected from different haematopoietic niches. With my new system, multiple cell lines from different haematopoietic sites at different developmental points are derived. Moreover, some of these lines demonstrated ability to mature precursors from E9.5 embryo (pro-HSCs) to definitive HSC without help of growth factors. This result is better compared to OP9 stromal lines. Such data proved usefulness of using stromal cell lines to study haematopoietic specification.

京都大学 / 新制・論文博士 / 博士(医学) / 乙第13441号 / 論医博第2240号 / 新制||医||1054(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 生田 宏一, 教授 滝田 順子, 教授 江藤 浩之 / 学位規則第4条第2項該当 / Doctor of Medical Science / Kyoto University / DFAM

Haematopoietic stem cells (HSC) are strictly regulated by intrinsic regulators and extrinsic signals from the microenvironment. Nov (CCN3), a matricellular protein of the CCN family, has been reported as a suppressor gene in solid tumours and chronic myeloid leukaemia (CML). Recent study identified Nov as a positive regulator in human cord blood CD34+ stem cells. However, the functions of Nov in haematopoiesis and adult HSC remain largely unknown.

Haematopoietic stem cells (HSCs) maintain the vertebrate blood system throughout life. Exploiting their clinical potential requires a thorough understanding of the natural origins of the HSCs. They first arise from the haemogenic endothelium (HE), located in the main embryonic artery, the dorsal aorta. Our understanding of the genetic mechanisms underlying HE specification remains incomplete, but one of the crucial transcription factors is Gata2. We found that a conserved enhancer of zebrafish gata2a gene (i4 enhancer) is active in vivo specifically in endothelial cells, including the HE. To unravel the function of gata2a in specifying the HSCs, we have targeted the i4 enhancer with CRISPR/Cas9, generating the first reported genomic deletion of an endogenous cis-regulatory region in zebrafish. Deletion of the i4 enhancer leads to a decrease in endothelial gata2a expression and a concomitant transient decrease in the number of HSCs. This is marked by an early decrease in the expression of gata2b, a gata2a paralogue previously shown to be required for the initiation of the haematopoietic programme. Our results suggest non-redundant roles of both zebrafish gata2 paralogues in programming of HSCs, providing insights into different roles of GATA2 throughout the programming of HSCs. We also confirmed the previously reported loss of HSCs upon MO-mediated knockdown of lmo4a, associated with increased gata2a expression in HE. We validated the increase in gata2a levels in TALEN-generated lmo4a mutants. To identify the links between lmo4a, gata2a and the HE programming, we have profiled the transcriptome of lmo4a-deficient endothelial cells, including the HE. Our results suggest that Lmo4a may be a global regulator of the transcriptional programming of the HE. Moreover, Wnt signalling pathway may regulate gata2a downstream of lmo4a. This provides novel insights into the gene regulatory network orchestrating the generation of HSCs in the embryo.

La maladie du greffon contre l’hôte (GVHD) reste la complication majeure de l’allogreffe de cellules soucheshématopoïétiques (allo-CSH). La GVHD résulte de l’activation de la réponse immunitaire et de la reconnaissanced’alloantigènes par les lymphocytes T (LT) du donneur, entrainant ainsi des lésions tissulaires principalement auniveau de la peau, des intestins et du foie. L’interleukine-22 (IL-22) est une cytokine sécrétée par les LT Th1,Th17 et les cellules de l’immunité innée (ILC). Compte tenu des propriétés de l’IL-22 dans les tissus cibles de laGVHD, nous avons évalué sa contribution dans la physiopathologie de la maladie à l’aide de modèlesexpérimentaux murins. Il apparaît que les souris qui reçoivent des lymphocytes T invalidés pour l’IL-22développent une maladie moins sévère, et leur mortalité est diminuée. L’IL-22 issue du greffon participe donc à lasévérité de la GVHD en favorisant l’inflammation systémique, mais aussi locale au niveau des organes cibles. Deplus, dans les intestins, l’IL-22 agit en synergie avec les interférons de type I pour amplifier l’inflammation de typeTh1 au cours de la GVHD. Chez l’homme, la GVHD est associée à une modification du microbiote intestinal.Nous avons montré que l’absence d’IL-22 semble favoriser la colonisation de lactobacilles au détriment declostridiums, ce qui pourrait également participer à la diminution de la GVHD intestinale. Enfin, nous avonsmontré que l’effet anti-tumoral est préservé malgré l’absence d’IL-22. Ces résultats permettent donc d’envisagerde nouvelles perspectives thérapeutiques dans le traitement de la GVHD. / Graft-versus-host disease (GVHD) is still the major complication after allogeneic stem cell transplantation. GVHDresults from the activation of the immune response and the recognition by donor T cells of alloantigens leading totissue injury, especially in skin, gut and liver. Interleukin-22 (IL-22) is a cytokine secreted by CD4+ T cells Th1 andTh17 but also by innate lymphoid cells (ILC). Given that IL-22 functions in the GVHD target tissues, weinvestigated its contribution in GVHD physiopathology using mouse experimental models. We showed that IL-22deficiency in donor cells reduced the severity of GVHD by limiting systemic and local inflammation. Moreover, inthe large intestine, IL-22 acts in synergy with type I interferon to increase Th1-like inflammation. In humans,GVHD severity is associated with microbiotal modification in the intestine. We demonstrated that IL-22 deficiencyin donor cells seems to favor lactobacillus colonization instead of clostridium. These changes of microbiotacomposition may reduce the severity of intestinal GVHD. Finally, we showed that the antitumor effect is preservedeven in absence of IL-22 donor cells. Overall, our data support the design of new clinical approaches aiming totarget IL-22 pathways in GVHD patients.

Qualificar as primeiras unidades de Sangue de Cordão Umbilical e Placentá- rio (SCUP) criopreservadas no Banco de Sangue Umbilical e placentário da Fundação de Hematologia e Hemoterapia de Pernambuco (BSCUP/HEMOPE), no período de dezembro de 2014 a junho de 2017. Justificativa: O sangue do cordão é rico em células progenitoras hematopoéticas (CPH), utilizado para transplante e tratamento de patologias benignas e malignas. Avaliar as primeiras unidades coletadas no BSCUP/ HEMOPE será de grande valia para sua caracterização, planejamento de ações de melhoria do processo, contribuindo para o aumento da eficácia dos transplantes. Métodos: Foram triadas gestantes sem histórico de diagnóstico para doenças transmissíveis pelo sangue, com gestação terminada em recém-nascido (RN) vivo; caracterizadas através das variáveis sociodemográficas: idade, idade gestacional, antecedentes obstétricos e cor da pele dos RN foram caracterizados pelas variáveis explicativas: Gênero e Peso; as amostras das mães foram coletadas no dia do parto ou em até 48h após. O tempo entre o término da coleta e o início da criopreservação da unidade das CPH não excedeu 48 horas. As unidades de SCUP foram avaliadas quanto ao volume, total de células nucleadas (TCN), quantificação de células CD 34+, contagem de eritroblastos viabilidade celular e contaminação microbiológica. Neste estudo foi avaliada a variável \"unidades adequadas ao uso em relação ao peso do receptor, tomando com o base o TCN e o peso de um provável receptor, assim categorizados: unidades <12,5 x10e8 para peso 12,5 para peso >50kg; Resultados: Volume Inicial (ml):(min.50,0; max.166,80); Volume final(mL): (min.19,07;max.21,75); TCN pré (x108): (min.6,0;max.27,80);TCN pós(x108): (min.5,0; max.22,6); Recuperação Celular (%): (min.0,67; max.39,50); CD34+(x106):(min.0,67;max.39,50);Viabilidade(%): (min.71,35max.100); Conclusão: Das 113 unidades armazenadas, 89 (78,76%) atendem a receptores < 50kg (crianças) e 24 (21,24%) atendem a receptores >50k (adultos). O inventário apresentou resultados em conformidades com o especificado na legislação vigente, portanto, qualificadas para atender à demanda transfusional de transplantes de CPH. / To qualify the first units of cryopreserved Umbilical Cord and Placental Blood (SCUP) in the Umbilical and Placental Blood Bank of the Hematology and Hemotherapy Foundation of the State of Pernambuco (BSCUP / HEMOPE), from December 2014 to June 2017 Rationale: Cord blood is rich in hematopoietic progenitor cells (HPC), used for transplantation and treatment of benign and malignant pathologies. Evaluating the first units collected in the BSCUP / HEMOPE will be of great value for its characterization, planning of actions to improve the process, contributing to increase the efficiency of transplants. Methods: Pregnant women with no history of diagnosis for blood-borne diseases were screened, with gestation terminated in live newborn (NB); characterized by the sociodemographic variables: age, gestational age, obstetric history and skin color, NB were characterized by the explanatory variables: Gender and Weight; the samples of the mothers were collected on the day of delivery or within 48 hours after delivery. The time between the end of the collection and the beginning of the cryopreservation of the MHC unit did not exceed 48 hours. SCUP units were evaluated for volume, total nucleated cells (TNC), CD34 + cell count, cell viability erythroblast counts, and microbiological contamination. In this study, the variable \"units suitable for use in relation to the weight of the receptor\" was evaluated, taking as base the TNC and the weight of a probable receiver, as follows: units <12.5 x10e8 for weight 12 , 5 for weight> 50 kg; Results: Initial volume (ml): (min.50.0, max.166.80); Final volume (mL): (min.19.07, max.21.75); TCN pre (x108): (min.6,0; max.27,80); TCN post (x108): (min.5,0; max.22,6); Cellular Recovery (%): (min.0.67, max.39,50); CD34 + (x106): (min.0.67, max.39.50); Viability (%): (min.71,35max.100); : Of the 113 stored units, 89 (78.76%) attend to receptors <50kg (children) and 24 (21.24%) attend receptors> 50k (adults). Conclusion: The inventory presented results in compliance with that specified in current legislation, therefore, qualified to meet the transfusional demand for HPC transplants.